NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER
30, 2019
(UNAUDITED)
|
1)
|
Business
Overview, Liquidity and Management Plans
|
Pressure
BioSciences, Inc. (“we”, “our”, the “Company”) is focused on solving the challenging problems
inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life
sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific
analysis. Sample preparation is often complex, time-consuming, and in our belief, one of the most error-prone steps of scientific
research. It is a widely used laboratory undertaking, the requirements of which drive what we believe is a large and growing worldwide
market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process.
It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology,
or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (45,000 psi or greater) to safely,
conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal,
plant, and microbial sources.
Our
pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and
ultra-high levels - at controlled temperatures and specific time intervals - to rapidly and repeatedly control the interactions
of biomolecules, such as DNA, RNA, proteins, lipids, and small molecules. Our laboratory instrument, the Barocycler®, and
our internally developed consumables product line, including PULSE® (Pressure Used to Lyse Samples for Extraction) Tubes,
other processing tubes, and application specific kits (which include consumable products and reagents) together make up our PCT
Sample Preparation System, or PCT SPS.
In
2015, together with an investment bank, we formed a subsidiary called Pressure BioSciences Europe (“PBI Europe”) in
Poland. We have 49% ownership interest with the investment bank retaining 51%. As of now, PBI Europe does not have any operating
activities and we cannot reasonably predict when operations will commence. Therefore, we do not have control of the subsidiary
and did not consolidate in our financial statements. PBI Europe did not have any operations in the nine months ended September
30, 2019 or in fiscal year 2018.
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates
the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative
cash flows from operations with respect to our pressure cycling technology business since our inception. As of September 30, 2019,
we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt
regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings
in the past and as described in Notes 6 and 7. In addition we raised cash through debt financing after September 30, 2019 as described
in Note 8. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully
completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future
will be successful. These financial statements do not include any adjustments that might result from this uncertainty.
|
3)
|
Interim
Financial Reporting
|
The
accompanying unaudited consolidated balance sheet as of December 31, 2018, which was derived from audited financial statements,
and the unaudited interim consolidated financial statements of Pressure BioSciences, Inc. as of and for the three and nine
months ended September 30, 2019 and 2018 have been prepared in accordance with accounting principles generally accepted in
the United States of America (“generally accepted accounting principles” or “GAAP”) for interim financial
information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles
for complete financial statements. In the opinion of management, all material adjustments (consisting of only normal recurring
adjustments) considered necessary for a fair presentation have been included. Operating results for the three months and nine
months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December
31, 2019. For further information, refer to the audited consolidated financial statements and footnotes thereto included in the
Company’s Annual Report on Form 10-K (the “Form 10-K”) for the fiscal year ended December 31, 2018 as filed
with the Securities and Exchange Commission on April 16, 2019.
|
4)
|
Summary
of Significant Accounting Policies
|
Principles
of Consolidation
The
consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq,
Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Reclassifications
Certain
prior year amounts have been reclassified to conform to our current year presentation.
Recent
Accounting Standards
In
July 2018, the FASB issued ASU 2018-07, Compensation- Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting as an amendment and update expanding the scope of Topic 718. The amendment specifies that Topic 718 now
applies to all share-based payment transactions, even non-employee awards, in which a grantor acquires goods or services to be
used or consumed in a grantor’s own operations by issuing share-based payment awards. Under the new guidance, awards to
nonemployees are measured on the grant date, rather than on the earlier of the performance commitment date or the date at which
the nonemployee’s performance is complete. Also, the awards would be measured by estimating the fair value of the equity
instruments to be issued, rather than the fair value of the goods or services received or the fair value of the equity instruments
issued, whichever can be measured more reliably. In addition, entities may use the expected term to measure nonemployee awards
or elect to use the contractual term as the expected term, on an award-by-award basis. The new guidance is effective for the Company
in annual periods beginning after December 15, 2018, and interim periods within those annual periods, with early adoption permitted.
Based on the new guidance, the Company will measure its nonemployee stock awards at grant date not when the stock awards are vested.
This new guidance did not have a material impact on the Company’s consolidated financial statements.
Revenue
Recognition
We
recognize revenue in accordance with FASB ASC 606, ASC 606, Revenue from Contracts with Customers, and ASC 340-40, Other
Assets and Deferred Costs—Contracts with Customers. Revenue is measured based on a consideration specified in a contract
with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. We enter into sales contracts
that may consist of multiple distinct performance obligations where certain performance obligations of the sales contract are
not delivered in one reporting period. We measure and allocate revenue according to ASC 606-10.
We
identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good
or service either on its own or together with other resources that are readily available to the customer and the entity’s
promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining
the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance
obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments.
Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over
time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While
changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for
a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect
on our financial position and result of operations. This is because the contract consideration is allocated to each performance
obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation.
Taxes
assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that
are collected by the Company from a customer, are excluded from revenue.
Shipping
and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for
as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods.
Our
current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support
a favorable first experience for our customers, upon customer request, and for an additional fee, will send a highly trained technical
representative to the customer site to install Barocycler®s that we sell, lease, or rent through our domestic sales force.
The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements
do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue.
The
majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time
of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the
product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the
shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers
to pay shortly after delivery and do not contain significant financing components.
We
apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash
transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges
would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following
conditions apply:
|
a)
|
The
fair value of the asset or service involved is not determinable.
|
|
|
|
|
b)
|
The
transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property
to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange.
|
|
|
|
|
c)
|
The
transaction lacks commercial substance.
|
We
currently record revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold.
In
accordance with FASB ASC 842, Leases, we account for our Barocycler lease agreements in which the Company is the lessor
under the operating method. The new standard provides a number of optional practical expedients in transition. We elected the
‘package of practical expedients’ for our instrument leases, which permits us not to reassess under the new standard
our prior conclusions about lease identification, lease classification and initial direct costs.
We
record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six-month
estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement
is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations.
Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement
with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the
term of the leases.
Revenue
from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award.
Deferred
revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized
because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably
over the length of the contract.
Disaggregation
of revenue
In
the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
In
thousands of US dollars ($)
|
|
Three
Months Ended
September 30,
|
|
|
Nine
Months Ended
September 30,
|
|
Primary
geographical markets
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
North
America
|
|
|
381
|
|
|
|
408
|
|
|
|
973
|
|
|
|
1,123
|
|
Europe
|
|
|
9
|
|
|
|
59
|
|
|
|
103
|
|
|
|
278
|
|
Asia
|
|
|
111
|
|
|
|
55
|
|
|
|
454
|
|
|
|
370
|
|
|
|
|
501
|
|
|
|
522
|
|
|
|
1,530
|
|
|
|
1,771
|
|
|
|
Three
Months Ended
September 30,
|
|
|
Nine
Months Ended
September 30,
|
|
Major
products/services lines
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Hardware
|
|
|
186
|
|
|
|
278
|
|
|
|
571
|
|
|
|
1,094
|
|
Grants
|
|
|
-
|
|
|
|
61
|
|
|
|
-
|
|
|
|
106
|
|
Consumables
|
|
|
112
|
|
|
|
43
|
|
|
|
265
|
|
|
|
182
|
|
Contract
research services
|
|
|
149
|
|
|
|
80
|
|
|
|
498
|
|
|
|
147
|
|
Sample
preparation accessories
|
|
|
19
|
|
|
|
22
|
|
|
|
61
|
|
|
|
118
|
|
Technical
support/extended service contracts
|
|
|
25
|
|
|
|
20
|
|
|
|
93
|
|
|
|
70
|
|
Shipping
and handling
|
|
|
8
|
|
|
|
10
|
|
|
|
27
|
|
|
|
38
|
|
Other
|
|
|
2
|
|
|
|
8
|
|
|
|
15
|
|
|
|
16
|
|
|
|
|
501
|
|
|
|
522
|
|
|
|
1,530
|
|
|
|
1,771
|
|
|
|
Three
Months Ended
September 30,
|
|
|
Nine
Months Ended
September 30,
|
|
Timing
of revenue recognition
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Products
transferred at a point in time
|
|
|
326
|
|
|
|
362
|
|
|
|
939
|
|
|
|
1,546
|
|
Products
and services transferred over time
|
|
|
175
|
|
|
|
160
|
|
|
|
591
|
|
|
|
225
|
|
|
|
|
501
|
|
|
|
522
|
|
|
|
1,530
|
|
|
|
1,771
|
|
Contract
balances
In
thousands of US dollars ($)
|
|
September
30, 2019
|
|
|
December
31, 2018
|
|
Receivables,
which are included in ‘Accounts Receivable’
|
|
|
411
|
|
|
|
475
|
|
Contract
liabilities (deferred revenue)
|
|
|
49
|
|
|
|
58
|
|
Transaction
price allocated to the remaining performance obligations
The
following table includes estimated revenue expected to be recognized in the future related to performance obligations that are
unsatisfied (or partially unsatisfied) at the end of the reporting period.
In
thousands of US dollars ($)
|
|
2019
|
|
|
2020
|
|
|
2021
|
|
|
Total
|
|
Extended
warranty service
|
|
|
27
|
|
|
|
22
|
|
|
|
-
|
|
|
|
49
|
|
All
consideration from contracts with customers is included in the amounts presented above.
Contract
Costs
The
Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the
assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and
administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized
either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life
of the contract so the Company records the costs immediately upon billing.
Beneficial
Conversion Features
In
accordance with FASB ASC 470-20, “Debt with Conversion and Other Options” the Company records a beneficial conversion
feature (“BCF”) related to the issuance of convertible debt or preferred stock instruments that have conversion features
at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating
a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally
calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other
securities into which the security is convertible, multiplied by the number of shares into which the security is convertible.
If certain other securities are issued with the convertible security, the proceeds are allocated among the different components.
The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares
to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute
the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.
Use
of Estimates
To
prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States
of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify
deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates
employed in our calculation of fair value of stock options awarded and warrant derivative liability. We base our estimates on
historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from
other sources. Actual results could differ from the estimates and assumptions used.
Concentrations
Credit
Risk
Our
financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents,
and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities.
We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by
the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic
laboratories.
The
following table illustrates the level of concentration as a percentage of total revenues during the three months and nine months
ended September 30, 2019 and 2018.
|
|
For
the Three Months Ended
|
|
|
|
September
30,
|
|
|
|
2019
|
|
|
2018
|
|
Top
Five Customers
|
|
|
56
|
%
|
|
|
59
|
%
|
Federal
Agencies
|
|
|
12
|
%
|
|
|
12
|
%
|
|
|
For
the Nine Months Ended
|
|
|
|
September
30,
|
|
|
|
2019
|
|
|
2018
|
|
Top
Five Customers
|
|
|
41
|
%
|
|
|
36
|
%
|
Federal
Agencies
|
|
|
13
|
%
|
|
|
10
|
%
|
The
following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30,
2019 and December 31, 2018. The Top Five Customers category may include federal agency receivable balances if applicable.
|
|
September
30, 2019
|
|
|
December,
31, 2018
|
|
Top
Five Customers
|
|
|
59
|
%
|
|
|
54
|
%
|
Federal
Agencies
|
|
|
10
|
%
|
|
|
5
|
%
|
Product
Supply
CBM
Industries (Taunton, MA) has recently become the manufacturer of the Barocycler® 2320EXT. CBM is ISO 13485:2003 and 9001:2008
Certified. CBM provides us with precision manufacturing services that include management support services to meet our specific
application and operational requirements. Among the services provided by CBM to us are:
|
●
|
CNC
Machining
|
|
|
|
|
●
|
Contract
Assembly & Kitting
|
|
|
|
|
●
|
Component
and Subassembly Design
|
|
|
|
|
●
|
Inventory
Management
|
|
|
|
|
●
|
ISO
certification
|
At
this time, we believe that outsourcing the manufacturing of our new Barocycler® 2320EXT to CBM is the most cost-effective
method for us to obtain and maintain ISO Certified, CE and CSA Marked instruments. CBM’s close proximity to our South Easton,
MA facility is a significant asset enabling interactions between our Engineering, R&D, and Manufacturing groups and their
counterparts at CBM. CBM was instrumental in helping PBI achieve CE Marking on our Barocycler® 2320EXT, as announced on February
2, 2017.
Although
we currently manufacture and assemble the Barozyme HT48, Barocycler® HUB440, the SHREDDER SG3, and most of our consumables
at our South Easton, MA facility, we plan to take advantage of the established relationship with CBM and transfer manufacturing
of the entire Barocycler® product line, future instruments, and other products to CBM.
Investment
in Equity Securities
As
of September 30, 2019, we held 100,250 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a
Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 321
“Investments —Equity Securities”. ASC 321 requires equity investments with readily determinable fair
values to be measured at fair value with changes in fair value recognized in net income. On September 30, 2019, our consolidated
balance sheet reflected the impaired value of our investment in Everest to be approximately $17,000.
Computation
of Loss per Share
Basic
loss per share is computed by dividing loss available to common shareholders by the weighted average number of shares of common
stock outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average
number of shares of common stock outstanding plus additional shares of common stock that would have been outstanding if dilutive
potential shares of common stock had been issued. For purposes of this calculation, convertible preferred stock, common stock
dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they
have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss.
The
following table illustrates our computation of loss per share for the three months and nine months ended September
30, 2019 and 2018:
|
|
For
the Three Months Ended
|
|
|
For
the Nine Months Ended
|
|
|
|
September
30,
|
|
|
September
30,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(3,156,829
|
)
|
|
$
|
(1,808,656
|
)
|
|
$
|
(7,978,844
|
)
|
|
$
|
(6,321,542
|
)
|
Deemed
dividend on down round feature
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(213,012
|
)
|
Deemed
dividend on beneficial conversion feature
|
|
|
(675,979
|
)
|
|
|
(1,146,280
|
)
|
|
|
(2,625,710
|
)
|
|
|
(11,678,571
|
)
|
Preferred
stock dividends
|
|
|
(492,494
|
)
|
|
|
(277,439
|
)
|
|
|
(1,268,593
|
)
|
|
|
(373,318
|
)
|
Net
loss applicable to common shareholders
|
|
$
|
(4,325,302
|
)
|
|
$
|
(3,232,375
|
)
|
|
$
|
(11,873,147
|
)
|
|
$
|
(18,586,443
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator
for basic and diluted loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average common stock shares outstanding
|
|
|
1,967,872
|
|
|
|
1,606,575
|
|
|
|
1,887,393
|
|
|
|
1,466,424
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
per common share – basic and diluted
|
|
$
|
(2.20
|
)
|
|
$
|
(2.01
|
)
|
|
$
|
(6.29
|
)
|
|
$
|
(12.67
|
)
|
The
following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented,
the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would
have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series
H Convertible Preferred Stock, Series H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible
Preferred Stock and Series AA Convertible Preferred Stock are presented below as if they were converted into shares of common
stock according to the conversion terms.
|
|
As
of September 30,
|
|
|
|
2019
|
|
|
2018
|
|
Stock
options
|
|
|
409,064
|
|
|
|
341,790
|
|
Convertible
debt
|
|
|
984,703
|
|
|
|
361,391
|
|
Common
stock warrants
|
|
|
9,297,034
|
|
|
|
6,769,607
|
|
Convertible
preferred stock:
|
|
|
|
|
|
|
|
|
Series
D Convertible Preferred Stock
|
|
|
25,000
|
|
|
|
25,000
|
|
Series
G Convertible Preferred Stock
|
|
|
26,857
|
|
|
|
26,857
|
|
Series
H Convertible Preferred Stock
|
|
|
33,334
|
|
|
|
33,334
|
|
Series
H2 Convertible Preferred Stock
|
|
|
70,000
|
|
|
|
70,000
|
|
Series
J Convertible Preferred Stock
|
|
|
115,267
|
|
|
|
115,267
|
|
Series
K Convertible Preferred Stock
|
|
|
229,334
|
|
|
|
229,334
|
|
Series
AA Convertible Preferred Stock
|
|
|
7,899,422
|
|
|
|
5,655,454
|
|
|
|
|
19,090,015
|
|
|
|
13,628,034
|
|
Accounting
for Stock-Based Compensation Expense
We
maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees,
independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the
requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.
Determining
Fair Value of Stock Option Grants
Valuation
and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing
model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line
method over the vesting period.
Expected
Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical
exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average
of the vesting period and the contractual life of the stock options granted.
Expected
Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the
award.
Risk-Free
Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield
currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.
Forfeitures
- The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated
a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company
used this historical rate as our assumption in calculating future stock-based compensation expense.
The
Company recognized stock-based compensation expense of $115,002 and $151,314 for the three months ended September
30, 2019 and 2018, respectively. The Company recognized stock-based compensation expense of $722,576 and $299,584
for the nine months ended September 30, 2019 and 2018, respectively. The following table summarizes the effect of this
stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of
Operations:
|
|
For
the Three Months Ended
|
|
|
For
the Nine Months Ended
|
|
|
|
September
30,
|
|
|
September
30,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Cost
of sales
|
|
$
|
5,468
|
|
|
$
|
4,698
|
|
|
$
|
25,865
|
|
|
$
|
4,698
|
|
Research
and development
|
|
|
22,464
|
|
|
|
28,444
|
|
|
|
107,037
|
|
|
|
59,592
|
|
Selling
and marketing
|
|
|
14,520
|
|
|
|
11,822
|
|
|
|
65,598
|
|
|
|
26,298
|
|
General
and administrative
|
|
|
72,550
|
|
|
|
106,350
|
|
|
$
|
524,076
|
|
|
|
208,996
|
|
Total
stock-based compensation expense
|
|
$
|
115,002
|
|
|
$
|
151,314
|
|
|
$
|
722,576
|
|
|
$
|
299,584
|
|
Fair
Value of Financial Instruments
Due
to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued
expenses approximate their fair value. Long-term liabilities are primarily related to convertible debentures and deferred revenue
with carrying values that approximate fair value.
The
issuances of our convertible promissory notes, common stock and common stock purchase warrants are accounted for
under the fair value and relative fair value method.
The
warrant is first analyzed per its terms as to whether it has derivative features or not. If the warrant is determined to be a
derivative, then it is measured at fair value using the Black Scholes Option Model and recorded as a liability on the balance
sheet. The warrant is re-measured at its then current fair value at each subsequent reporting date (it is “marked-to-market”).
If
the warrant is determined to not have derivative features, it is recorded into equity at its fair value using the Black Scholes
option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including
the fair value of the convertible note or preferred stock.
The
convertible note is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to
the total fair value including the fair value of the note, common stock and/or warrant. Further, upon issuance or modification,
we examine the convertible promissory note for any intrinsic beneficial conversion feature (“BCF”) of which
the convertible price of the note is less than the closing stock price on date of issuance. If the relative fair value method
is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using
an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the
convertible debt is converted into by its terms. The adjusted BCF value is accounted for as equity. Any warrant and BCF relative
fair values are also recorded as a corresponding debt discount to the convertible notes.
Fair
Value Measurements
The
Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”)
as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial
statements on a recurring basis.
In
determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a
hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable
inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would
use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs
are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset
or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken
down into three levels based on the source of inputs as follows:
Level
1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company
has the ability to access.
Level
2–Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or
similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either
directly or indirectly.
Level
3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
Financial
assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value
measurement. The Company has determined that its financial assets are classified within Level 1 and its financial liabilities
are currently classified within Level 3 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair
value measurements and fair value calculations are the responsibility of the Company’s management.
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of September 30, 2019:
|
|
|
|
|
Fair
value measurements at
September 30, 2019 using:
|
|
|
|
September 30,
2019
|
|
|
Quoted
prices in
active
markets
(Level 1)
|
|
|
Significant
other
observable
inputs
(Level 2)
|
|
|
Significant
unobservable
inputs
(Level 3)
|
|
Equity
Securities
|
|
|
16,643
|
|
|
|
16,643
|
|
|
|
-
|
|
|
|
-
|
|
Total
Financial Assets
|
|
$
|
16,643
|
|
|
$
|
16,643
|
|
|
$
|
-
|
|
|
$
|
-
|
|
The
following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring
basis as of December 31, 2018:
|
|
|
|
|
Fair
value measurements at
December 31, 2018 using:
|
|
|
|
December
31,
2018
|
|
|
Quoted
prices in
active
markets
(Level 1)
|
|
|
Significant
other
observable
inputs
(Level 2)
|
|
|
Significant
unobservable
inputs
(Level 3)
|
|
Equity
Securities
|
|
|
16,643
|
|
|
|
16,643
|
|
|
|
-
|
|
|
|
-
|
|
Total
Financial Assets
|
|
$
|
16,643
|
|
|
$
|
16,643
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Leases
(Topic 842)
The
Company has early adopted ASU No. 2016-02, Leases (Topic 842). The amendment requires companies to recognize leased assets and
liabilities on the balance sheet and to disclose key information regarding lease arrangements. This guidance is effective for
annual periods, and interim periods within those annual periods, after December 15, 2018. Early application of this amendment
is permitted for all entities. While we do not anticipate that going forward, leases will be material to our balance sheet, we
chose to early-adopt as of December 31, 2018. We have one lease that is required to be included on our balance sheet under the
new standard. This lease is an operating lease and, therefore, will have no income statement impact resulting from the adoption
of this standard.
|
5)
|
Commitments
and Contingencies
|
Operating
Leases
As
disclosed in Note 4, the Company early adopted ASC 842 to our existing leases. The Company has elected to apply the short-term
lease exception to leases of one year or less. Consequently, as a result of adoption of ASC 842, we recognized an operating liability
of $136,385 with a corresponding Right-Of-Use (“ROU”) asset of the same amount based on present value of the minimum
rental payments of the lease which is included in non-current assets and long-term liabilities in the consolidated balance sheet.
The discount rate used for leases accounted for under ASC 842 is the Company’s estimated borrowing rate of 25%.
Our
corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $6,950
per month, on a lease extension, signed on December 28, 2018, that expires December 31, 2019, for our corporate office. We expanded
our space to include offices, a warehouse and a loading dock on the first floor starting May 1, 2017 with a monthly rent increase
already reflected in the current payments.
We
extended our lease for our space in Medford, MA to December 30, 2020. The lease requires monthly payments of $7,130.50 subject
to annual cost of living increases. The lease can be extended by the Company for an additional three years unless either party
terminates at least six months prior to the expiration of the current lease term.
Rental
costs are expensed on a straight-line basis subject to future cost of living increases that are not known until the anniversary
date of each year. During the nine months ended September 30, 2019 and 2018 we incurred $135,864 and $137,074 in rent expense,
respectively for the use of our corporate office and research and development facilities.
Following
is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable
lease terms in excess of one year as of September 30, 2019:
For
the three months ending December 31, 2019
|
|
$
|
20,738
|
|
2020
|
|
|
82,953
|
|
2021
|
|
|
|
|
2022
|
|
|
-
|
|
Thereafter
|
|
|
-
|
|
|
|
$
|
103,691
|
|
|
6)
|
Convertible
Debt and Other Debt
|
Conversion
of Notes
We
issued 5,075.40 shares of our Series AA Convertible Preferred Stock in satisfaction of $12,688,635 of convertible promissory
notes, Revolving Note and short-term loans issued:
|
|
Debt
converted
to stock
|
|
Current
liabilities
|
|
|
|
|
Convertible
Debentures, face value
|
|
$
|
6,962,635
|
|
Revolving
Note with interest
|
|
|
4,750,000
|
|
May
19, 2017 Promissory Note with interest
|
|
|
750,000
|
|
Other
Notes with interest
|
|
|
226,000
|
|
Total
debt converted during the year 2018
|
|
$
|
12,688,635
|
|
Senior
Secured Convertible Debentures and Warrants
We
entered into Subscription Agreements (the “Subscription Agreement”) with various individuals (each, a “Purchaser”)
between July 23, 2015 and March 31, 2016, pursuant to which the Company sold Senior Secured Convertible Debentures (the “Debentures”)
and warrants to purchase shares of common stock equal to 50% of the number of shares issuable pursuant to the subscription amount
(the “Warrants”) for an aggregate purchase price of $6,329,549 (the “Purchase Price”).
The
Company issued a principal aggregate amount of $6,962,504 in Debentures which includes a 10% original issue discount on the Purchase
Price. The Debenture does not accrue any additional interest during the first year it is outstanding but accrues interest at a
rate equal to 10% per annum for the second year it is outstanding. The Debenture has a maturity date of two years from issuance.
The Debenture is convertible any time after its issuance date. The Purchaser has the right to convert the Debenture into shares
of the Company’s common stock at a fixed conversion price equal to $8.40 per share, subject to applicable adjustments. In
the second year that the Debenture is outstanding, any interest accrued shall be payable quarterly in either cash or common stock,
at the Company’s discretion. On September 11, 2017, we notified Debenture holders that their Debentures will be extended
180 days beyond the original maturity date as permitted in the Debenture agreement. We will continue to pay interest on the Debentures
until the extended maturity date. We accounted for the Debenture extensions as debt modifications and not extinguishment of debt
since the changes in fair value are not substantial in accordance with ASC 470-50. We started amortizing the remaining unamortized
discount as of September 11, 2017 over the new term, which extends 180 days beyond the original maturity date.
In
connection with the Debentures issued, the Company issued warrants exercisable into a total of 376,759 shares of our common stock.
The Warrants issued in this transaction are immediately exercisable at an exercise price of $12.00 per share, subject to applicable
adjustments including full ratchet anti-dilution if we issue any securities at a price lower than the exercise price then in effect.
The Warrants have an expiration period of five years from the original issue date. The Warrants are subject to adjustment for
stock splits, stock dividends or recapitalizations and also include anti-dilution price protection for subsequent equity sales
below the exercise price.
On
May 2, 2018, the Company entered into a Securities Purchase Agreement with an existing shareholder pursuant to which the Company
sold an aggregate of 100 shares of Series AA Convertible Preferred Stock for an aggregate Purchase Price of $250,000. We issued
to the shareholder a new warrant to purchase 100,000 shares of common stock with an exercise price of $3.50 per share and an expiration
period of five years from the original issue date.
The
Company, pursuant to a price protection provision triggered on May 2, 2018 with the sale of Series AA Convertible Preferred Stock,
amended the Debentures and Warrants to purchase Common Stock held by the Debenture Holders entered into between July 22, 2015
and March 31, 2016 as first disclosed in the Company’s Current Report on Form 8-K filed on July 28, 2015. The fair value
of $207,899 relating to the reduction in exercise price was treated as a deemed dividend and recorded as a charge against additional
paid-in capital within equity. The amended Debenture conversion price was exempt from revaluation because a beneficial conversion
feature had already been recorded on the Debenture at issuance.
Subject
to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right
to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTCQB (or other primary
trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price
of the Warrants for 15 out of 20 consecutive trading days.
In
connection with the Subscription Agreement and Debenture, the Company entered into Security Agreements with the Purchasers whereby
the Company agreed to grant to Purchasers an unconditional and continuing, first priority security interest in all of the assets
and property of the Company to secure the prompt payment, performance and discharge in full of all of Company’s obligations
under the Debentures, Warrants and the other Transaction Documents. On May 14 and June 11, 2018, the Company signed letter agreements
with the Debenture holders as explained below that discharged all of the Company’s obligations within the Debenture Agreement
Conversion
of Debentures
On
May 14, 2018, we entered into letter agreements (the “Letter Agreements”) with 22 investors (each a “Debenture
Holder” and together the “Debenture Holders”) holding convertible debentures (collectively the “Debentures”)
and warrants to purchase common stock (the “Debenture Warrants”) whereby the Debenture Holders agreed to convert a
total of $6,220,500 in principal and original issue discount due them under the Debentures into 2,448.20 shares of Series AA Convertible
Preferred Stock with a conversion price of $2.50 per share. The Debenture Holders were also: (a) issued amended Debenture Warrants
such that the exercise price will be $3.50 per share; and (b) issued a new warrant with an exercise price of $3.50 per share to
purchase 2,448,200 shares of common stock (the number of shares of common stock issuable upon conversion of the Series AA Convertible
Preferred Stock shares received as a result of the Debenture conversions). The Debenture Holders also agreed to waive any and
all defaults or events of default by the Company with respect to any failure by the Company to comply with any covenants contained
in the Debentures. The fair value of $29,865 relating to the adjustment in exercise price was treated as a loan modification and
recorded as a gain toward the extinguishment of debt.
On
June 11, 2018, the Company entered into additional Letter Agreements with 15 Debenture Holders whereby the Debenture Holders agreed
to convert a total of $742,135 in principal and original issue discount due to them under the Debentures into 296.80 shares of
Series AA Convertible Preferred Stock with a conversion price of $2.50 per share. The Debenture Holders were also: (a) issued
amended Debenture Warrants such that the exercise price will be $3.50 per share; and (b) issued a new warrant with an exercise
price of $3.50 per share to purchase 296,800 shares of common stock (the number of shares of common stock issuable upon conversion
of the Series AA Convertible Preferred Stock shares received as a result of the Debenture conversions). The Debenture Holders
also agreed to waive any and all defaults or events of default by the Company with respect to any failure by the Company to comply
with any covenants contained in the Debentures. The fair value of $3,155 relating to the adjustment in exercise price was treated
as a loan modification and recorded as a gain toward the extinguishment of debt.
In
connection with the above Debenture conversions and cancellation of the debt term, the Company recorded the full amount of the
remaining unamortized Debenture discounts of $157,908 as interest expense by June 11, 2018. The Company recorded $287,676 of the
Debenture discounts during 2018 through the cancellation date of June 11, 2018.
On
various dates for the nine months ended September 30, 2018, the Company issued 56,007 shares of common stock
based on the 10-day VWAP prior to quarter end to holders of the Debentures in payment of the quarterly interest accrued from the
Debentures first anniversary date through December 31, 2017 for an aggregate amount of $211,047. We recognized a $9,615
gain on extinguishment of debt by calculating the difference of the shares valued on the issuance date and the amount of accrued
interest through June 11, 2018.
Convertible
notes
The
Company, pursuant to a price protection provision triggered on May 2, 2018 with the sale of Series AA Convertible Preferred Stock,
amended the conversion price of a March 12, 2018 loan to $2.50 per share. The fair value of $253,000, limited to the face value
of the loan, relating to the reset in the conversion price was recorded as a debt discount and amortized as interest expense over
the remaining loan term.
On
various dates during the nine months ended September 30, 2019, the Company issued convertible notes for net proceeds
of approximately $4.6 million which contained varied terms and conditions as follows: a) maturity dates ranging from 2
to 12 months; b) interest rates that accrue per annum ranging from 3% to 15%; c) convertible into the Company’s common
stock at issuance at a fixed rate of $2.50 to $7.50 or convertible at variable conversion rates either after 6 months after
issuance or in the event of a default. Certain of these notes were issued with shares of common stock that were fair valued at
issuance dates. The aggregate relative fair value of $226,133 of the shares of common stock issued with the notes was recorded
as a debt discount and amortized over the term of the notes. During the nine months ended September 30, 2019 we also have evaluated
our convertible notes (upon issuance or modification) for any beneficial conversion feature (“BCF”), reporting the
BCF as additional paid in capital and debt discount of $451,665. Finally, we evaluate the convertible notes for derivative liability
treatment on an on-going basis and have determined that all our notes did not qualify for derivative accounting treatment as of
September 30, 2019. In this period, the amortization of this debt discount was $362,056 and as of September 30, 2019 the unamortized
BCF debt discount was $89,610.
The
specific terms of the convertible notes that are outstanding as of September 30, 2019 are listed in the tables below.
Loan
Inception
Date
|
|
Term
|
|
|
Loan
Amount
|
|
|
Outstanding
Balance with OID
|
|
|
Original
Issue Discount
|
|
|
Interest
Rate
|
|
|
Conversion
Price
|
|
|
Deferred
Finance Fees
|
|
|
Discount
related to fair value of conversion feature and warrants/shares
|
|
February
15, 2018 (1),(2),(3)
|
|
|
6
months
|
|
|
$
|
100,000
|
|
|
$
|
115,000
|
|
|
|
|
|
|
|
15
|
%
|
|
$
|
2.5
|
|
|
$
|
9,000
|
|
|
$
|
14,106
|
|
May
17, 2018 (1),(2)
|
|
|
12
months
|
|
|
$
|
380,000
|
|
|
$
|
191,703
|
|
|
$
|
15,200
|
|
|
|
8
|
%
|
|
$
|
2.5
|
|
|
$
|
15,200
|
|
|
$
|
188,007
|
|
May
30, 2018 (1),(2)
|
|
|
2
months
|
|
|
$
|
150,000
|
|
|
$
|
75,000
|
|
|
$
|
-
|
|
|
|
8
|
%
|
|
$
|
7.5
|
|
|
$
|
-
|
|
|
$
|
6,870
|
|
June
8, 2018 (1)
|
|
|
6
months
|
|
|
$
|
50,000
|
|
|
$
|
50,000
|
|
|
$
|
2,500
|
|
|
|
15
|
%
|
|
$
|
7.5
|
|
|
$
|
2,500
|
|
|
$
|
3,271
|
|
June
12, 2018 (1)
|
|
|
6
months
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
-
|
|
|
|
5
|
%
|
|
$
|
7.5
|
|
|
$
|
5,000
|
|
|
$
|
-
|
|
June
16, 2018 (1)
|
|
|
9
months
|
|
|
$
|
130,000
|
|
|
$
|
79,000
|
|
|
$
|
-
|
|
|
|
5
|
%
|
|
$
|
(4
|
)
|
|
$
|
-
|
|
|
$
|
-
|
|
June
16, 2018 (1)
|
|
|
6
months
|
|
|
$
|
110,000
|
|
|
$
|
79,000
|
|
|
$
|
-
|
|
|
|
5
|
%
|
|
$
|
(4
|
)
|
|
$
|
-
|
|
|
$
|
-
|
|
June
26, 2018 (1),(3)
|
|
|
3
months
|
|
|
$
|
150,000
|
|
|
$
|
86,250
|
|
|
$
|
-
|
|
|
|
15
|
%
|
|
$
|
2.5
|
|
|
$
|
-
|
|
|
$
|
25,507
|
|
June
28, 2018 (1)
|
|
|
6
months
|
|
|
$
|
50,000
|
|
|
$
|
50,000
|
|
|
$
|
-
|
|
|
|
15
|
%
|
|
$
|
7.5
|
|
|
$
|
-
|
|
|
$
|
10,518
|
|
July
17, 2018 (1),(3)
|
|
|
3
months
|
|
|
$
|
100,000
|
|
|
$
|
105,000
|
|
|
$
|
15,000
|
|
|
|
15
|
%
|
|
$
|
2.5
|
|
|
$
|
-
|
|
|
$
|
46,597
|
|
July
19, 2018 (1)
|
|
|
12
months
|
|
|
$
|
184,685
|
|
|
$
|
150,000
|
|
|
$
|
34,685
|
|
|
|
10
|
%
|
|
$
|
7.5
|
|
|
$
|
-
|
|
|
$
|
-
|
|
October
19, 2018 (1),(2)
|
|
|
6
months
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
-
|
|
|
|
5
|
%
|
|
$
|
7.5
|
|
|
$
|
-
|
|
|
$
|
-
|
|
November
13, 2018 (1),(3)
|
|
|
6
months
|
|
|
$
|
200,000
|
|
|
$
|
220,000
|
|
|
$
|
-
|
|
|
|
15
|
%
|
|
$
|
2.5
|
|
|
$
|
-
|
|
|
$
|
99,330
|
|
January 2, 2019
|
|
|
12
months
|
|
|
$
|
125,000
|
|
|
$
|
112,500
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
2.5
|
|
|
$
|
6,250
|
|
|
$
|
6,620
|
|
January 3, 2019 (1)
|
|
|
6
months
|
|
|
$
|
50,000
|
|
|
$
|
50,000
|
|
|
$
|
2,500
|
|
|
|
15
|
%
|
|
$
|
7.5
|
|
|
$
|
2,500
|
|
|
$
|
-
|
|
February 21, 2019
|
|
|
12
months
|
|
|
$
|
215,000
|
|
|
$
|
215,000
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
2.75
|
|
|
$
|
15,000
|
|
|
$
|
96,764
|
|
February 22, 2019
|
|
|
9
months
|
|
|
$
|
115,563
|
|
|
$
|
115,562
|
|
|
$
|
8,063
|
|
|
|
7
|
%
|
|
$
|
7.5
|
|
|
$
|
2,500
|
|
|
$
|
-
|
|
March 18, 2019 (2)
|
|
|
6
months
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
7.5
|
|
|
$
|
-
|
|
|
$
|
10,762
|
|
June 4, 2019
|
|
|
9
months
|
|
|
$
|
500,000
|
|
|
$
|
500,000
|
|
|
$
|
-
|
|
|
|
8
|
%
|
|
$
|
2.5
|
|
|
$
|
40,500
|
|
|
$
|
70,631
|
|
May 15, 2019
|
|
|
12
months
|
|
|
$
|
75,000
|
|
|
$
|
75,000
|
|
|
$
|
7,500
|
|
|
|
5
|
%
|
|
|
(4
|
)
|
|
$
|
2,000
|
|
|
$
|
4,235
|
|
May 28, 2019
|
|
|
12
months
|
|
|
$
|
115,500
|
|
|
$
|
115,500
|
|
|
$
|
5,500
|
|
|
|
8
|
%
|
|
$
|
2.75
|
|
|
$
|
-
|
|
|
$
|
22,354
|
|
May 14, 2019
|
|
|
12
months
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
-
|
|
|
|
6
|
%
|
|
$
|
7.5
|
|
|
$
|
2,000
|
|
|
$
|
-
|
|
April 30, 2019
|
|
|
12
months
|
|
|
$
|
105,000
|
|
|
$
|
105,000
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
7.5
|
|
|
$
|
5,000
|
|
|
$
|
3,286
|
|
June 19, 2019
|
|
|
12
months
|
|
|
$
|
105,000
|
|
|
$
|
105,000
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
7.5
|
|
|
$
|
5,000
|
|
|
$
|
2,646
|
|
April 9, 2019
|
|
|
12
months
|
|
|
$
|
118,800
|
|
|
$
|
118,800
|
|
|
$
|
8,800
|
|
|
|
4
|
%
|
|
$
|
7.5
|
|
|
$
|
3,000
|
|
|
$
|
-
|
|
May 6, 2019
|
|
|
12
months
|
|
|
$
|
150,000
|
|
|
$
|
150,000
|
|
|
$
|
-
|
|
|
|
6
|
%
|
|
$
|
7.5
|
|
|
$
|
7,500
|
|
|
$
|
3,534
|
|
May 7, 2019
|
|
|
6
months
|
|
|
$
|
155,000
|
|
|
$
|
155,000
|
|
|
$
|
5,000
|
|
|
|
0
|
%
|
|
$
|
7.5
|
|
|
$
|
-
|
|
|
$
|
12,874
|
|
April 23, 2019
|
|
|
10
months
|
|
|
$
|
103,000
|
|
|
$
|
103,000
|
|
|
$
|
-
|
|
|
|
8
|
%
|
|
|
(4
|
)
|
|
$
|
3,000
|
|
|
$
|
-
|
|
May 17, 2019
|
|
|
10
months
|
|
|
$
|
103,000
|
|
|
$
|
103,000
|
|
|
$
|
-
|
|
|
|
8
|
%
|
|
|
(4
|
)
|
|
$
|
3,000
|
|
|
$
|
-
|
|
April
10, 20 19 (1),(3)
|
|
|
3
months
|
|
|
$
|
75,000
|
|
|
$
|
86,250
|
|
|
$
|
-
|
|
|
|
5
|
%
|
|
$
|
2.5
|
|
|
$
|
-
|
|
|
$
|
37,054
|
|
May 20, 2019 (1)
|
|
|
3
months
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
-
|
|
|
|
5
|
%
|
|
$
|
2.5
|
|
|
$
|
-
|
|
|
$
|
13,439
|
|
June 7, 2019
|
|
|
6
months
|
|
|
$
|
125,000
|
|
|
$
|
125,000
|
|
|
$
|
-
|
|
|
|
5
|
%
|
|
$
|
7.5
|
|
|
$
|
-
|
|
|
$
|
18,254
|
|
July 1, 2019
|
|
|
12
months
|
|
|
$
|
107,500
|
|
|
$
|
107,500
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
4.0
|
|
|
$
|
7,500
|
|
|
$
|
11,246
|
|
July 8, 2019
|
|
|
12
months
|
|
|
$
|
65,000
|
|
|
$
|
65,000
|
|
|
$
|
-
|
|
|
|
5
|
%
|
|
|
(4
|
)
|
|
$
|
8,500
|
|
|
$
|
4,376
|
|
July 10, 2019
|
|
|
9
months
|
|
|
$
|
112,500
|
|
|
$
|
112,500
|
|
|
$
|
-
|
|
|
|
8
|
%
|
|
|
(4
|
)
|
|
$
|
3,000
|
|
|
$
|
-
|
|
July 19, 2019
|
|
|
6
months
|
|
|
$
|
250,000
|
|
|
$
|
250,000
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
7.5
|
|
|
$
|
-
|
|
|
$
|
36,835
|
|
July 19, 2019
|
|
|
12
months
|
|
|
$
|
115,000
|
|
|
$
|
115,000
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
7.5
|
|
|
$
|
5,750
|
|
|
$
|
3,989
|
|
July 19, 2019
|
|
|
12
months
|
|
|
$
|
130,000
|
|
|
$
|
130,000
|
|
|
$
|
-
|
|
|
|
6
|
%
|
|
$
|
7.5
|
|
|
$
|
6,500
|
|
|
$
|
-
|
|
August 6, 2019
|
|
|
12
months
|
|
|
$
|
108,000
|
|
|
$
|
108,000
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
7.5
|
|
|
$
|
11,000
|
|
|
$
|
-
|
|
August 14, 2019
|
|
|
6
months
|
|
|
$
|
50,000
|
|
|
$
|
50,000
|
|
|
$
|
-
|
|
|
|
3
|
%
|
|
$
|
7.5
|
|
|
$
|
-
|
|
|
$
|
-
|
|
August 27, 2019
|
|
|
10
months
|
|
|
$
|
113,000
|
|
|
$
|
113,000
|
|
|
$
|
-
|
|
|
|
8
|
%
|
|
|
(4
|
)
|
|
$
|
3,000
|
|
|
$
|
-
|
|
September 11, 2019
|
|
|
12
months
|
|
|
$
|
50,000
|
|
|
$
|
50,000
|
|
|
$
|
-
|
|
|
|
6
|
%
|
|
|
(4
|
)
|
|
$
|
6,500
|
|
|
$
|
3,823
|
|
September 13, 2019
|
|
|
12
months
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
-
|
|
|
|
6
|
%
|
|
$
|
2.50
|
|
|
$
|
2,000
|
|
|
$
|
-
|
|
September
27, 2019
|
|
|
12
months
|
|
|
$
|
78,750
|
|
|
$
|
78,750
|
|
|
$
|
-
|
|
|
|
4
|
%
|
|
$
|
2.50
|
|
|
$
|
3,750
|
|
|
$
|
13,759
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
5,620,298
|
|
|
$
|
5,215,315
|
|
|
$
|
104,748
|
|
|
|
|
|
|
|
|
|
|
$
|
186,450
|
|
|
$
|
770,687
|
|
(1)
The notes were extended for an additional term.
(2)
The note is currently past due. The Company and the lender are
negotiating in good faith to extend the loan.
(3)
Interest was capitalized and added to outstanding principal amount.
(4)
Note is not currently convertible.
For
the nine months ended September 30, 2019, the Company recognized amortization expense related to the debt discounts indicated
above of $830,181. The unamortized debt discounts as
of September 30, 2019 related to the convertible debentures and other convertible notes amounted to $326,380.
Revolving
Note Payable and May 19, 2017 Promissory Note
On
October 28, 2016, an accredited investor (the “Investor”) purchased from us a promissory note in the aggregate principal
amount of up to $2,000,000 (the “Revolving Note”) due and payable on the earlier of October 28, 2017 (the “Maturity
Date”) or on the seventh business day after the closing of a Qualified Offering (as defined in the Revolving Note). Although
the Revolving Note is dated October 26, 2016, the transaction did not close until October 28, 2016, when we received its initial
$250,000 advance pursuant to the Revolving Note. As a result, on the same day and pursuant to the Revolving Note, we issued to
the Investor a Common Stock Purchase Warrant to purchase 20,834 shares of our common stock at an exercise price per share equal
to $12.00 per share. The Investor is obligated to provide us with advances of $250,000 under the Revolving Note, but the Investor
shall not be required to advance more than $250,000 in any individual fifteen (15) day period and no more than $500,000 in the
thirty (30) day period immediately following the date of the initial advance. We received $3,500,000 pursuant to the Revolving
Note as amended of which $2,070,000 net proceeds was received in 2017 and we issued to the Investor warrants to purchase 291,667
shares of our Common Stock at an exercise price per share equal to $12.00 per share. The terms of the Warrants are identical except
for the exercise date, issue date, and termination date which are based on the advance date.
The
Revolving Note was amended on May 2, 2017 to increase the aggregate principal amount to $3,000,000, to issue 16,667 shares of
our Common Stock to the Investor, to decrease the exercise price per share of the warrants to the lower of (i) $12.00 or (ii)
the per share purchase price of the shares of our Common Stock sold in the Qualified Offering, and to change the references in
the Revolving Note from “the six (6) month anniversary of October 28, 2016” to “July 25, 2017.” The fair
value of the 16,667 shares issued of $149,018 was accounted for as a note discount and are amortized to interest expense over
the life of the loan. We evaluated the accounting impact of the Revolving Note amendment and deemed that the amendment did not
have a material impact on our consolidated financial statements.
The
Revolving Note was amended on August 18, 2017 to increase the aggregate principal amount to $3,500,000 with all other terms unchanged.
The Revolving Note, previously amended, was further amended on January 30, 2018 to increase the aggregate principal amount to
$4,000,000 with all other terms unchanged.
In
the event that a Qualified Offering had occurred after July 25, 2017, but prior to the Maturity Date, within seven (7) Business
Days of the closing of the Qualified Offering, the Company was to pay a cash fee equal to five percent (5%) of the total outstanding
amount owed by the Company to the Holder as of the closing date of the Qualified Offering or, at the option of the Company, issue
to the Holder a number of restricted shares of the Company’s common stock equal to (x) five percent (5%) of the total outstanding
amount owed by the Company to the Holder as of the closing date of the Qualified Offering divided by (y) the purchase price provided
by the documents governing the Qualified Offering. A “Qualified Offering” means the completion of a public offering
of the Company’s securities pursuant to which the Company receives aggregate gross proceeds of at least Seven Million United
States Dollars (US$7,000,000) in consideration of the purchase of its securities and resulting in, pursuant to the effectiveness
of the registration statement for such offering, the Company’s common stock being traded on the NASDAQ Capital Market, NASDAQ
Global Select Market or the New York Stock Exchange. A Qualified Offering did not occur on or prior to the Maturity Date.
Interest
on the principal balance of the Revolving Note and fees of $95,000 were converted into 38 shares of Series AA Convertible Preferred
Stock with a conversion price of $2.50 per share as discussed below.
Broker
fees amounting to $336,500, the one-time interest of $400,000 and the relative fair value of the 333,334 warrants issued to the
Investor amounting to $1,266,691 were recorded as debt discounts and amortized over the term of the revolving note. The unamortized
debt discounts related to the Revolving Note were fully amortized as of December 31, 2017. The finance costs from advances after
December 31, 2017 were charged to interest expense directly because the maturity date had passed.
On
May 19, 2017, we received a 45-day non-convertible loan of $630,000 from the Investor. The loan provided guaranteed interest of
$63,000 and had an origination fee of $32,000. We paid a broker $31,500 in connection with this loan.
Conversion
of October 26, 2016 Revolving Note and May 19, 2017 Promissory Note
On
June 11, 2018, the Company entered into a Letter Agreement with the Investor to convert a total of $5,500,000 in principal and
interest due to the Investor pursuant to the Revolving Note and the May 19, 2017 promissory note into 2,200 shares of Series AA
Convertible Preferred Stock with a conversion price of $2.50 per share. The Company also amended the Line of Credit Warrants held
by the Investor. The Company lowered the Line of Credit Warrants’ exercise price from $12.00 per share to $3.50 per share.
The fair value of $82,904 relating to the reduction in exercise price was treated as a loan modification and recorded as a charge
against the extinguishment of debt.
The
Company also issued a new warrant to the Investor with an exercise price of $3.50 per share to purchase 2,200,000 shares of common
stock (the number of shares of common stock issuable upon conversion of the Series AA Convertible Preferred Stock shares received
as a result of the conversion of a total of $5,500,000). In connection with the Letter Agreement, the Investor also waived $520,680
of interest and fees owed as of September 30, 2018. We recognized $520,680 as a gain on extinguishment of debt.
Convertible
Loan Modifications and Extinguishments
We
refinanced certain convertible loans during the nine months ended September 30, 2019 at substantially the same terms
for extensions of ranging from three to six months. We amortized any remaining unamortized debt discount as of the modification
date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments
which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different
maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions.
According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor
in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if
the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present
value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or
modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to
be substantially different and will be accounted for as modifications.
The
cash flows of new debt exceeded 10% of the remaining cash flows of the original debt on seventeen loans in the nine
months of 2019. We recorded losses on debt extinguishment of $332,474 for the nine months ended September 30, 2019
by calculating the difference of the fair value of the new debt and the carrying value of the old debt. The loss was primarily
from the fair value of common stock issued in connection with these refinancings and cash fees paid.
On
various dates in the nine months ended September 30, 2019, two lenders converted $300,000 of amounts owed into 120,000 shares
of common stock. The amount converted included $200,797 of principal and $141,453 of interest and fees.
The
Company’s Chief Executive Officer is personally guaranteeing $190,000 of convertible debt of which $190,000 is outstanding
as of September 30, 2019.
The
following table provides a summary of the changes in convertible debt and revolving note payable, net of unamortized discounts,
during 2019:
|
|
2019
|
|
Balance
at January 1,
|
|
$
|
4,000,805
|
|
Issuance
of convertible debt, face value
|
|
|
4,964,613
|
|
Deferred
financing cost
|
|
|
(285,813
|
)
|
Debt
discount from shares issued with the notes
|
|
|
(262,904
|
)
|
Contingent
BCF on convertible notes
|
|
|
(451,665
|
)
|
Conversion
of debt into equity
|
|
|
(200,797
|
)
|
Payments
|
|
|
(3,705,485
|
)
|
Accretion
of interest and amortization of debt discount to interest expense
|
|
|
830,181
|
|
Balance at
September 30,
|
|
$
|
4,888,935
|
|
Less:
current portion
|
|
|
4,888,935
|
|
Convertible
debt, long-term portion
|
|
$
|
-
|
|
Other
Notes
In
March 2018, we received non-convertible loans totaling $150,000 from private investors. The loans include one-year term and 10%
guaranteed interest. We converted these loans into Series AA Convertible Preferred Stock and common stock warrants. See below.
In
April 2018, we received a non-convertible loan for $10,000 from a private investor. The loan includes a one-year term and 10%
guaranteed interest. We converted this loan into Series AA Convertible Preferred Stock and common stock warrants. See below.
As
further disclosed on page 24, during the nine months ended September 30, 2019 we signed various Merchant Agreements which are
secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates
from 31% to 47%. Under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed
Purchase Amount, which is collected by the Merchant lenders at the disclosed Daily Payment Rate.
On
September 9, 2019, we received a non-convertible loan for $400,000 from a private investor. The loan includes $95,000 of interest
and fees through October 9, 2019. The loan is currently past due and the Company
and the Investor are negotiating in good faith to extend the loan including interest and late fees owed.
On
October 1, 2019, the Company and the holder of the $170,000 convertible loan issued in May 2017 agreed to extend the terms of
the loan until December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains
outstanding. The loan will continue to earn 10% annual interest.
Merchant
Agreements
We
have signed various Merchant Agreements which entitle the lenders to our customer receipts. We accounted for the Merchant Agreements
as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts.
Under the agreements below we received the Purchase Price, of which approximately in exchange for rights to all customer receipts
until the lender is paid the Purchased Amount, which is collected at the rate of the Daily Payment per business day. The difference
between the Purchased Amount and Purchase price is imputed interest that will be recorded as interest expense when paid each day.
The Deferred Finance fees below were paid on the inception date. The payments were secured by second position rights to all customer
receipts until the loan has been paid in full.
The
following table shows our Merchant Agreements as of September 30, 2019.
Inception
Date
|
|
Purchase
Price
|
|
|
Purchased
Amount
|
|
|
Outstanding
Balance
|
|
|
Daily
Payment
Rate
|
|
|
Deferred
Finance Fees
|
|
August
5, 2019
|
|
|
600,000
|
|
|
|
816,000
|
|
|
|
503,439
|
|
|
|
4,533.33
|
|
|
|
6,000
|
|
August
19, 2019
|
|
|
350,000
|
|
|
|
479,500
|
|
|
|
309,565
|
|
|
|
2,664.00
|
|
|
|
3,000
|
|
August
23, 2019
|
|
|
175,000
|
|
|
|
239,750
|
|
|
|
158,321
|
|
|
|
1,410.00
|
|
|
|
1,750
|
|
September
19, 2019
|
|
|
275,000
|
|
|
|
384,275
|
|
|
|
273,948
|
|
|
|
2,137.36
|
|
|
|
5,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,400,000
|
|
|
$
|
1,919,525
|
|
|
$
|
1,245,273
|
|
|
|
|
|
|
$
|
15,750
|
|
See
Note 8, Subsequent Events.
We
amortized $31,797 and $56,769 of debt discounts during the nine months ended September 30, 2019 and 2018, respectively
for all non-convertible notes. The total unamortized discount for all non-convertible notes as of September 30, 2019 was $7,036.
The
Company’s Chief Executive Officer is personally guaranteeing $1,245,273 of loans outstanding as of September
30, 2019. These loans include debt through certain merchant agreements.
Conversion
of Non-Convertible Notes
On
June 11, 2018, the Company entered into Letter Agreements with certain private investors to convert a total of $176,000 in principal
and interest due to the private investors pursuant to certain loan documents into 70.4 shares of Series AA Convertible Preferred
Stock with a conversion price of $2.50 per share and warrants to purchase 70,400 shares of common stock and an expiration period
of five years from the original issue date.
Related
Party Notes
In
June 2018, we received a non-convertible loan of $15,000 from a private investor. The loan includes a one-year term and 10% guaranteed
interest. This loan remains outstanding as of September 30, 2019.
During
the nine months ended September 30, 2019, we received short-term non-convertible loans of $239,000 from related
parties (a member of the Company’s Board of Directors and Company Officers). The loans were repaid in full as of September
30, 2019 except for $79,000.
Preferred
Stock
We
are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock:
|
1)
|
20,000
shares have been designated as Series A Junior Participating Preferred Stock (“Junior A”)
|
|
|
|
|
2)
|
313,960
shares have been designated as Series A Convertible Preferred Stock (“Series A”)
|
|
|
|
|
3)
|
279,256
shares have been designated as Series B Convertible Preferred Stock (“Series B”)
|
|
|
|
|
4)
|
88,098
shares have been designated as Series C Convertible Preferred Stock (“Series C”)
|
|
|
|
|
5)
|
850
shares have been designated as Series D Convertible Preferred Stock (“Series D”)
|
|
|
|
|
6)
|
500
shares have been designated as Series E Convertible Preferred Stock (“Series E”)
|
|
|
|
|
7)
|
240,000
shares have been designated as Series G Convertible Preferred Stock (“Series G”)
|
|
|
|
|
8)
|
10,000
shares have been designated as Series H Convertible Preferred Stock (“Series H”)
|
|
|
|
|
9)
|
21
shares have been designated as Series H2 Convertible Preferred Stock (“Series H2”)
|
|
|
|
|
10)
|
6,250
shares have been designated as Series J Convertible Preferred Stock (“Series J”)
|
|
|
|
|
11)
|
15,000
shares have been designated as Series K Convertible Preferred Stock (“Series K”)
|
|
|
|
|
12)
|
10,000
shares have been designated as Series AA Convertible Preferred Stock (“Series AA”)
|
As
of September 30, 2019, there were no shares of Junior A, and Series A, B, C, and E issued and outstanding. See our Annual
Report on Form 10-K for the year ended December 31, 2018 for the pertinent disclosures of preferred stock.
Series
AA Convertible Preferred Stock and Warrants
During
the nine months ended September 30, 2019, the Company entered into Securities Purchase Agreements with shareholders
pursuant to which the Company sold an aggregate of 1,415.6 shares of Series AA Convertible Preferred Stock, each preferred
share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share, for an aggregate Purchase
Price of $3,539,000. Each share of Series AA Convertible Preferred Stock will receive a cumulative dividend at the annual
rate of eight percent (8%) payable quarterly commencing on March 31, 2019 on those shares of Series AA Convertible Preferred Stock
purchased from the Company. Broker fees amounted to $353,900 in cash and warrants to purchase 142,280 shares of common stock
with a term of five years and an exercise price of $3.50 with relative fair values of $397,860.
We
issued to the shareholders warrants to purchase 1,415,600 shares of common stock with an exercise price of $3.50 per share.
The Warrant will expire on the fifth-year anniversary after issuance. The exercise price is also subject to adjustment in the
event that we issue any shares of common stock or common stock equivalents at a per share price that is lower than the exercise
price for the Series AA Warrants then in effect. Upon any such issuance, subject to certain exceptions, the exercise price will
be reduced to the per share price at which such shares of common stock or common stock equivalents are issued.
Shareholders
converted 16 shares of Series AA Convertible Preferred Stock into 16,000 shares of common stock as of September 30, 2019.
Stock
Options and Warrants
Our
stockholders approved our amended 2005 Equity Incentive Plan (the “Plan”) pursuant to which an aggregate of 1,800,000
shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards made under the Plan.
Under the Plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers,
directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. The Plan expired and
on July 18, 2018, the outstanding options to acquire 32,605 shares were transferred as discussed below to one of the other plans.
At
the Company’s December 12, 2013 Special Meeting, the shareholders approved the 2013 Equity Incentive Plan (the “2013
Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options
or other equity awards. Under the 2013 Plan, we may award stock options, shares of common stock, and other equity interests in
the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems
appropriate. As of September 30, 2019, options to acquire 409,064 shares were outstanding under the Plan with 2,590,936
shares available for future grant under the 2013 Plan.
On
July 18, 2018, the Board of Directors approved the immediate termination of 244,467 outstanding stock options held by current
officers, employees and board members (32,605 stock options under the 2005 Plan, 81,925 stock options under the 2013 Plan, and
129,937 stock options under the 2015 Plan) and the issuance of new stock options to the same holders with an exercise price of
$3.40 per share equal to the closing market price on July 18, 2018 and an expiration date of July 18, 2028. The new stock options
for board members will vest 1/12th per month for 12 months. The new stock options for officers and employees will vest 1/36th
per month for 36 months. The 2005 Plan expired in 2015 so of the 32,605 terminated stock options, 16,641 stock options were issued
under the 2013 Plan and 15,964 stock options were issued under the 2015 Plan (in addition to the reissuance of 81,925 stock options
under the 2013 Plan, and 129,937 stock options under the 2015 Plan). The Board of Directors also awarded 101,267 stock options
to officers, employees and board members separately based on the annual compensation committee recommendation. Of the 101,267
stock options issued, 51,934 stock options were issued under the 2013 Plan and 49,333 stock options were issued under the 2015
Plan.
On
November 5, 2018 the Board of Directors approved the closing of the 2015 Plan and moved the 203,734 options outstanding in the
2015 Plan into the 2013 Plan which was then the only option plan still active. The unamortized expense related to this transfer
is $108,400 which will be amortized over the remaining life of the options.
We
evaluated this exchange and concluded that it was a modification under ASU 2017-09. Under ASU 2017-09, a cancelled equity award
accompanied by the concurrent grant of (or offer to grant) a replacement award or other valuable consideration shall be accounted
for as a modification of the terms of the cancelled award. Therefore, incremental compensation cost shall be measured as the excess
of the fair value of the replacement award or other valuable consideration over the fair value of the cancelled award at the cancellation
date in accordance with paragraph ASC 718-20-35-3. The total compensation cost measured at the date of a cancellation and replacement
shall be the portion of the grant-date fair value of the original award for which the requisite service is expected to be rendered
(or has already been rendered) at that date plus the incremental cost resulting from the cancellation and replacement. The compensation
value created by the termination and issuance of new stock options, as determined under the Black Scholes method, was approximately
$759,469 and under ASU 2017-09 results in a non-cash expense in current and future periods not to exceed the vesting periods of
the stock options.
As
of September 30, 2019, total unrecognized compensation cost related to the unvested stock-based awards was $562,295,
which is expected to be recognized over weighted average period of 0.81 years. The aggregate intrinsic value associated
with the options outstanding and exercisable and the aggregate intrinsic value associated with the warrants outstanding and exercisable
as of September 30, 2019, based on the September 30, 2019 closing stock price of $2.74, was zero.
The
following tables summarize information concerning options and warrants outstanding and exercisable:
|
|
Stock
Options
|
|
|
Warrants
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Average
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
Price
per share
|
|
|
Shares
|
|
|
Price
per share
|
|
|
Total
Shares
|
|
|
Total
Exercisable
|
|
Balance
outstanding, 12/31/18
|
|
|
366,734
|
|
|
$
|
3.39
|
|
|
|
7,764,821
|
|
|
$
|
3.50
|
|
|
|
8,131,555
|
|
|
|
7,792,570
|
|
Granted
|
|
|
62,550
|
|
|
|
-
|
|
|
|
1,557,214
|
|
|
|
3.50
|
|
|
|
1,619,764
|
|
|
|
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
Expired
|
|
|
-
|
|
|
|
-
|
|
|
|
(25,001
|
)
|
|
|
14.82
|
|
|
|
(25,001
|
)
|
|
|
|
|
Forfeited
|
|
|
(20,220
|
)
|
|
|
3.40
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(20,220
|
)
|
|
|
|
|
Balance
outstanding, 9/30/2019
|
|
|
409,064
|
|
|
$
|
3.39
|
|
|
|
9,297,034
|
|
|
$
|
3.56
|
|
|
|
9,706,098
|
|
|
|
9,486,855
|
|
|
|
|
Options
Outstanding
|
|
|
Options
Exercisable
|
|
|
|
|
Weighted
Average
|
|
|
Weighted
Average
|
|
Range
of
Exercise
Prices
|
|
|
Number
of Options
|
|
|
Remaining
Contractual
Life (Years)
|
|
Exercise
Price
|
|
|
Number
of Options
|
|
|
Remaining
Contractual Life (Years)
|
|
Exercise
Price
|
|
|
$
2.00 - $3.40
|
|
|
|
409,064
|
|
|
9.2
|
|
$
|
3.39
|
|
|
|
189,821
|
|
|
9.1
|
|
$
|
3.40
|
|
|
$
2.00 - $3.40
|
|
|
|
409,064
|
|
|
9.2
|
|
$
|
3.39
|
|
|
|
189,821
|
|
|
9.1
|
|
$
|
3.40
|
|
Common
Stock Issuances
During
the nine months ended September 30, 2018, we issued to Debenture holders 56,007 shares of common stock for quarterly interest
of $201,432 issued in stock in lieu of cash. Of the 56,007 shares issued, 4,681 shares were issued to members of the Company’s
Board of Directors, who are also Debenture holders.
On
various dates during the nine months ended September 30, 2018 the Company issued a total of 194,236 shares of restricted
common stock at a fair value of $949,952 to accredited investors. 14,200 of the shares with a fair value of $53,618
were issued to existing holders of convertible loans who agreed to extend the terms of the loans for various months; 85,238
shares with a fair value of $286,172 were issued in conjunction with the signing of new convertible loans; and 110,833
shares with a fair value of $652,894 were issued in connection with a letter agreement dated June 11, 2018. During the nine
months ended September 30, 2018 the Company also issued 48,000 shares with a fair value of $173, 520 for services rendered.
During
the nine months ended September 30, 2019, we issued Series AA holders 61,910 shares of common stock for dividends totaling $190,123
issued in stock in lieu of cash. Of the 61,910 shares issued, 5,432 were issued to members of the Company’s Board of Directors,
who are also Series AA holders. During this period shareholders also converted 16 shares of Series AA Convertible Preferred Stock
into 16,000 shares of common stock.
On
various dates during the nine months ended September 30, 2019 the Company issued a total of 335,069 shares of restricted common
stock at a fair value of $953,515 to accredited investors. 140,937 of the shares with a fair value of $385,132 were issued to
existing holders of convertible loans who agreed to extend the terms for various months; 74,132 of the shares with a fair value
of $226,133 were issued in conjunction with the signing of new convertible loans; and 120,000 shares were issued for the conversion
of $342,250 of convertible notes and related interest. During the nine months ended September 30, 2019 the company also issued
75,000 shares with a fair value of $245,000 were issued for services rendered.
From
October 1, 2019 through December 13, 2019 the Company issued Convertible notes for a total of $806,750. The
notes required 5,000 shares of the Company’s common stock to be issued and included interest at rates ranging from
4% to 8% and are for terms of nine to twelve months. The Company also extended five Convertible notes (see below schedule)
and issued 6,200 shares to settle a conversion of a convertible loan. Finally, during this period the Company extended a $170,000
non-convertible loan from a private investor to December 31, 2019 (with no extension or interest paid).
From
October 1, 2019 through December 13, 2019 the
Company issued 40 shares of Series AA Convertible Preferred Stock at $2,500 per share and received $90,000 net of
$10,000 of broker fees. For every $2,500 invested, the investor received one share of Series AA Convertible Preferred Stock
convertible into 1,000 shares of Common Stock and 1,000 warrants to purchase Common Stock at $3.50 per share and an expiration
period of five years from the original issue date.
On
November 15, 2019 and December 3, 2019, the Company entered into two Securities Purchase Agreements (the “SPAs”) with
the same private investor (the “Investor”), pursuant to which the Investor purchased from the Company, for a total
purchase price of $800,000 (the “Purchase Price”): (i) 10% Senior Secured Convertible Promissory Notes in the total
principal amount of $880,000 (the “Notes”); and (ii) common stock purchase warrants permitting the Investor to purchase
up to a total of 176,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”),
at an exercise price of $3.50 per share (the “Warrants”, and together with the Notes, the “Securities”).
The Notes accrue interest
at a rate of ten percent (10%) per annum and mature on November 15, 2020 and December 3, 2020 (the “Maturity Dates”).
The Notes contains customary events of default (each an “Event of Default”). If an Event of Default occurs, all outstanding
obligations owing under the Notes will become immediately due and payable at the Investor’s election. Any outstanding obligations
owing under the Notes which is not paid when due shall bear interest at the rate of eighteen percent (18%) per annum. The Notes
are convertible into shares of the Company’s Common Stock, subject to the adjustments described therein. The conversion
price (the “Conversion Price”) shall equal to $2.50.
In connection with
the issuance of the Notes, the Company entered into a General Security Agreement (the “GSA”) with the Investor whereby
the Company granted to the Investor a continuing security interest in, lien upon and a right of setoff against, all of the Company’s
right, title and interest in all of the Company’s assets.
In connection with
the SPAs, the Company entered into Registration Rights Agreements (the “RRAs”) pursuant to which it shall (i) use
its best efforts to file initial registration statement on Form S-1 (the “Registration Statement”) with the U.S. Securities
and Exchange Commission (the “Commission”) to register the Securities, within thirty (30) calendar days after
the final closing date of the Company’s offering of Series AA Convertible Preferred Stock (the “Filing Deadline);
and (ii) have the Registration Statement declared effective by the Commission within one hundred fifty (150) days of the Filing
Deadline.
In connection with
the SPAs, the Company payed a 10% cash fee (a total of $80,000), to Garden State Securities, Inc. (the “Placement Agent”)
for acting as placement agent for the sale of the Securities. The Company will also issue a warrant to the Placement Agent for
it to purchase shares of Common Stock equal to ten percent (10%) of the Securities.
On November 15, 2019,
the Company reached a verbal agreement with its Merchant Agreement lenders to temporarily reduce the Daily Payment Rate from $10,744
to $2,500.
Convertible
Loan Modifications and Extinguishments
Subsequent
to September 30, 2019, the Company modified or paid off the following loans:
Loan Inception Date
|
|
Principal
|
|
|
Principal and interest
paid
|
|
|
Extinguished or Extended
|
|
|
|
|
|
|
|
|
|
July 19,2018
|
|
$
|
150,000
|
|
|
$
|
22,500
|
|
|
Conversion term extended to January 19, 2020
|
|
|
|
|
|
|
|
|
|
|
|
April 9,2019
|
|
$
|
118,000
|
|
|
$
|
10,000
|
|
|
Conversion term extended to November 15, 2019
|
|
|
|
|
|
|
|
|
|
|
|
April 23,2019
|
|
$
|
103,000
|
|
|
$
|
143,146
|
|
|
Repaid after September 30, 2019
|
|
|
|
|
|
|
|
|
|
|
|
May 6, 2019
|
|
$
|
150,000
|
|
|
$
|
206,889
|
|
|
Repaid after September 30, 2019
|
|
|
|
|
|
|
|
|
|
|
|
May 7, 2019
|
|
$
|
155,000
|
|
|
$
|
201,500
|
|
|
Repaid after September 30, 2019
|
|
|
|
|
|
|
|
|
|
|
|
May 14, 2019
|
|
$
|
100,000
|
|
|
$
|
136,000
|
|
|
Repaid after September 30, 2019
|
|
|
|
|
|
|
|
|
|
|
|
May 17, 2019
|
|
$
|
103,000
|
|
|
$
|
103,000
|
|
|
Repaid after September 30, 2019
|
|
|
|
|
|
|
|
|
|
|
|
January 2, 2019
|
|
$
|
125,000
|
|
|
$
|
15,000
|
|
|
Conversion term extended to December 9, 2019
|
|
|
|
|
|
|
|
|
|
|
|
February 20, 2019
|
|
$
|
115,563
|
|
|
$
|
16,627
|
|
|
Conversion term extended to February 20, 2020
|
|
|
|
|
|
|
|
|
|
|
|
June 4, 2019
|
|
$
|
500,000
|
|
|
|
(1
|
)
|
|
Conversion term extended to December 4, 2019
|
(1)
Loan extended after issuance of 50,000 common stock warrants.